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Adrenal tumors evoke considerable interest and represent various diagnostic challenges. Adrenal tumors
can be stratiﬁed into adrenal medullary and adrenocortical tumors. Approximately 60% of adrenocortical
tumors are hormonally active and show speciﬁc signs and symptoms. Patients with a nonfunctioning
adrenal tumor usually present with abdominal discomfort due to the mass effect of the tumor. An
imaging feature that differentiates benign from malignant adrenal neoplasms is the tumor size. Thus, for
the differential diagnosis of adrenal lesions, measurement of the Hounsﬁeld units on an unenhanced
computed tomographic scan is of great value when differentiating malignant from benign lesions.
Herein, we describe a young female patient who presented with a huge left suprarenal tumor. She
underwent complete resection of the adrenal tumor. The ﬁnal pathological diagnosis was an adreno-
cortical carcinoma. There has been no evidence of recurrence for the last 4 years.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Suprarenal tumors evoke considerable interest and represent
various diagnostic challenges to physicians. Adrenal tumors
consists the most portion of suprarenal tumors, which can be
stratiﬁed into adrenal medullary and adrenocortical tumors.
Approximately 60% of adrenocortical tumors are hormonally active
and show speciﬁc signs and symptoms. Patients with a nonfunc-
tioning adrenal tumor usually present with abdominal discomfort
due to the mass effect of the tumor. An imaging feature that
differentiates benign from malignant adrenal neoplasms is the
tumor size. Based on the report of this case and subsequent review
of the literatures, measurement of the Hounsﬁeld units on an
unenhanced computed tomographic scan is of great value when
differentiating malignant from benign lesions.
2. Case report
A 36-year-old woman was referred from the nephrology
clinic due to the presence of a palpable mass in her left loin
region. She denied any symptoms such as abdominal pain, face
ﬂushing, headaches, weight loss, or any other systemicung Shan Medical University
ng 402, Taiwan.
ciation. Published by Elsevier Taiwsymptoms. There was also no contributory medical history. A
physical examination revealed the presence of a palpable mass
over the upper left quadrant of the abdomen that extended up
to the ﬂank region; however, the mass lesion was not found to
be tender. Results of abdominal computed tomography (CT)
scan revealed a huge left suprarenal mass. There were evidences
of calciﬁcation and central necrosis within the tumor, which had
also downwardly displaced the left kidney (Figs. 1A and 1B). All
laboratory tests were normal, including urinalysis, complete
blood count, and serum chemical studies. An adrenal endocrine
survey, including cortisol, testosterone, aldosterone, proges-
terone, and catecholamine, was also within normal limits.
Metastatic evaluation, including a whole-body bone scan and
positron emission tomography (PET), revealed a hot spot in the
right temporal bone. However, there was no bony lesion on the
plain skull ﬁlm.
2.1. Differential diagnosis
Abdominal CT scan after contrast medium enhancement
revealed an inhomogeneous mass with irregular enhancement of
the solid components. Calciﬁcations and central necrosis were also
visible. No surrounding tissues or organs were involved. The
possible differential diagnoses were adrenal medullary-type
tumors (pheochromocytomas and rare ganglioneuromas), adre-
nocortical tumors [adenomas, myelolipomas, oncocytic neoplasms,
and adrenocortical carcinomas (ACCs)], neurogenic tumors (such asan LLC. Open access under CC BY-NC-ND license.
Fig. 1. (A) Noncontrast unenhanced computed tomographic (CT) scan revealing a well-deﬁned huge mass with severe necrosis and evident calciﬁcations. (B) Contrast-enhanced CT,
showing a delayed attenuation of approximately 56e78 HU (on an approximately 10e15-minute delayed enhanced CT).
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tiocytomas and leiomyosarcomas). As is the case with any mass
involving the adrenal glands, it is important to differentiate the
lesion from an adrenal adenoma. An imaging feature that differ-
entiates benign from malignant adrenal neoplasms is the tumor
size.1 A diameter of <5 cm usually suggests a benign origin.
Furthermore, measurement of the Hounsﬁeld units on an unen-
hanced CT scan is of great value when differentiating malignant
from benign lesions. An attenuation value of >10 HU on an unen-
hanced CT scan or an enhancement washout of <50% and delayed
attenuation of >35 HU (on approximately 10e15-minute delayed
enhanced CT scan) suggests a malignancy.2 This young female
patient had a giant nonfunctional suprarenal tumor that gave
attenuation values of approximately 26e35 HU on the unenhanced
CT scans and values of approximately 56e78 HU on enhanced CT
scans, and therefore, an ACC was suspected. However, it was not
possible to rule out the rare possibility of an oncocytic neoplasm,
because a pathological feature that is useful when identifying an
adrenal oncocytic tumor is a ﬁbrous capsule.3
2.2. Management
Considering the huge size of the mass and the potential possi-
bility of malignancy, the patient underwent open surgery via
a transabdominal approach using a subcostal incision; this facili-
tated maximal exposure for the complete surgical excision of the
tumor and also minimized tumor spillage. An ovoid, well-
circumscribed tumor (16  9  8.5 cm) distinct from the leftFig. 2. (A) Microscopic analysis revealed the presence of obvious nucleoli, mitotic activity, an
and eosin stain (400). (B) Immunohistochemical analysis revealed that the tumor cells wkidney was found. The tumor had compressed the spleen and
pancreas and stretched the descending colon, but had not invaded
these organs. The tumor was completely removed. The patient was
discharged on the 6th day after the operation. No adjuvant
chemotherapeutic drug such as mitotane was administered. The
patient has had regular follow-ups including chest X-rays and CT
scans every 3 months and a yearly PET scan. There has been no
evidence of recurrence over the last 4 years.2.3. Pathology
The ﬁnal pathological diagnosis was an ACC. Upon sectioning,
we found that the encapsulated tumor was a heterogeneous mass
with a brownish-pink to yellow color on the cut surface and
showed multiple areas of myxoid change and necrosis. The surgical
margin was free of tumor. A microscopic examination revealed
a mass composed of round to polygonal neoplastic cells with
abundant eosinophilic cytoplasm (Fig. 2A). These nuclei were
hyperchromatic and pleomorphic, and had obvious nucleoli and
mitotic activity [2 per 50 high power ﬁelds (HPFs)]. Tumor necrosis
was evident. Neither capsular nor vascular invasion was identiﬁed.
The pathological stage was T2N0M0 (European Network for the
Study of Adrenal Tumor, the ENSAT staging system). Immunohis-
tochemical analysis revealed that the tumor cells were strongly
positive for cytokeratin (Fig. 2B) and desmin, but were weakly
positive for vimentin and S-100 protein, and negative for Ki67
(Fig. 2C).d eosinophilic tumor cell cytoplasmwhen the sections were stained with hematoxylin
ere strongly positive for cytokeratin (200) and (C) negative for Ki67 (100).
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All incidentally discovered adrenal masses should be checked
for excess hormonal secretions, including cortisol, aldosterone, and
catecholamine. The most common complaint associated with
nonfunctional adrenal tumors is abdominal pain and/or a palpable
tumor. The most common ﬁrst-line imaging modality is a CT scan.
Typical radiographic features associated with a malignant adrenal
tumor are a large size (>5 cm), vague borders, an irregular shape,
and a heterogeneous texture. However, in the end, ACC is a histo-
logical diagnosis, and a pathological diagnosis may be difﬁcult due
to the lack of clear-cut morphological criteria. The Weiss score is
most widely used when grading the microscopic features that are
suggestive of a malignant tumor. The classiﬁcation includes nine
histological criteria which can predict adrenocortical tumors that
metastasize or recur. We noticed a high nuclear grade (Fuhrman
grade: approximately 3e4), a high mitotic rate (>5/50 HPF), atyp-
ical mitotic ﬁgures, eosinophilic tumor cell cytoplasm, a diffuse
architecture present in 33% of the tumor, necrosis, invasion of
venous structures, invasion of sinusoidal structures, and capsular
invasion.4 Immunohistochemical stains such as Ki67 can be used
for both differentiating benign from malignant tumors and deter-
mining the prognosis of ACC. A Ki67 index of>7% is associated with
signiﬁcantly shortened disease-free survival.5
The treatment of choice and the only chance to cure ACC is
complete resection of the tumor, and if necessary, an adjacent
lymphadenectomy is mandatory for a cure. The anterior abdominal
approach offers easy access to the main vessels and good exposure
that prevents tumor spillage when resecting larger tumors. The
long-term outcome did not signiﬁcantly differ between the use of
a laparoscopic adrenalectomy and open surgery for tumors of
<10 cm.6 Adjuvant therapy is recommended for most patients
because of the risk of recurrence, which is high at approximately
60e80%.7 Mitotane can be administered to treat inoperable tumorsand metastatic disease or when there is incomplete resection.
Radiation therapy of the tumor bed is recommended for patients
with a histologically incomplete (R1) or undetermined (Rx) resec-
tion. Based on the tumor-free resection margin and the negative
immunostaining for Ki67, adjuvant treatment was not suggested to
this patient.
An ACC is a rare malignancy, and a multidisciplinary approach
has the best chance to provide optimizedmanagement of this lethal
orphan disease. An improved understanding of the pathogenesis of
this malignancy and a collaborative effort will lead to therapeutic
advances that may improve treatment outcomes.Conﬂicts of interest statement
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